Neumora Therapeutics (NMRA) Research & Development (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Research & Development of $38.6 million for Q1 2026, down 25.99% year-over-year from $52.2 million in Q1 2025, and down 13.59% quarter-over-quarter from $44.7 million in Q4 2025.
Neumora Therapeutics (NMRA) Research & Development (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Research & Development history runs 5 years deep, the most recent figure standing at $38.6 million for Q1 2026.
- In Q1 2026, Research & Development fell 25.99% year-over-year to $38.6 million; the TTM figure through Mar 2026 stood at $162.5 million (down 21.61% YoY), while the FY2025 annual figure was $176.1 million, down 12.37% from the prior year.
- Research & Development for Q1 2026 stood at $38.6 million, down from $44.7 million in the prior quarter.
- The five-year high for Research & Development was $60.6 million in Q3 2024, with the low at $22.5 million in Q3 2022.
- The 5-year median for Research & Development is $40.5 million (2025), against an average of $40.3 million.
- The sharpest annual moves came in 2023 and 2025: Research & Development jumped 84.49% in 2023, then sank 33.17% in 2025.
- Neumora Therapeutics' Research & Development stood at $23.5 million in 2022, then jumped by 65.22% to $38.9 million in 2023, then climbed by 18.14% to $45.9 million in 2024, then decreased by 2.71% to $44.7 million in 2025, then slipped by 13.59% to $38.6 million in 2026.
- Business Quant data shows NMRA's Research & Development at $38.6 million in Q1 2026, $44.7 million in Q4 2025, and $40.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 38.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.60 Mn |
| Dec 31, 2025 | 44.67 Mn |
| Sep 30, 2025 | 40.52 Mn |
| Jun 30, 2025 | 38.72 Mn |
| Mar 31, 2025 | 52.15 Mn |
| Dec 31, 2024 | 45.91 Mn |
| Sep 30, 2024 | 60.63 Mn |
| Jun 30, 2024 | 48.63 Mn |
| Mar 31, 2024 | 45.76 Mn |
| Dec 31, 2023 | 38.86 Mn |
| Sep 30, 2023 | 41.60 Mn |
| Jun 30, 2023 | 32.77 Mn |
| Mar 31, 2023 | 29.49 Mn |
| Dec 31, 2022 | 23.52 Mn |
| Sep 30, 2022 | 22.55 Mn |